TIDMINC

RNS Number : 8748C

Incanthera PLC

23 June 2021

23 June 2021

Incanthera plc

("Incanthera" or the "Company")

Result of AGM 2021

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed.

The Company would like to thank all Shareholders who returned their Proxy form and for their compliance with the current Government measures surrounding non-essential travel and public gatherings.

For further enquiries:

 
Incanthera plc 
 www.incanthera.com 
 
 Tim McCarthy, Chairman 
 tim.mccarthy@incanthera.com                  +44 (0) 7831 675747 
 
 Simon Ward, Chief Executive Officer 
 simon.ward@incanthera.com                    +44 (0) 7747 625506 
 
 Suzanne Brocks, Head of Communications 
 suzanne.brocks@incanthera.com                +44 (0) 7776 234600 
 
Aquis Exchange Corporate Adviser: 
 Cairn Financial Advisers LLP 
 Jo Turner/James Lewis                       +44 (0) 20 7213 0880 
 
Broker: 
 Stanford Capital Partners Ltd 
 Patrick Claridge/John Howes/Bob Pountney    +44 (0) 20 3815 8880 
 

Notes to Editors

Incanthera is a specialist oncology company focused on innovative technologies in oncology and dermatology . It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

@incantheraplc

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXKZGZVMFVGMZM

(END) Dow Jones Newswires

June 23, 2021 07:59 ET (11:59 GMT)

Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Apr 2022 a Mag 2022 Clicca qui per i Grafici di Incanthera
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Mag 2021 a Mag 2022 Clicca qui per i Grafici di Incanthera